Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
about
The management of type 2 diabetic patients with hypoglycaemic agentsRandomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND RegistryEmerging gliptins for type 2 diabetes.Diabetes-related alterations in the enteric nervous system and its microenvironment.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Association of musculoskeletal complaints and gliptin use: review of spontaneous reports.A retrospective review of isolated gliptin-exposure cases reported to a state poison control system.Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.DPP-4 inhibitors: pharmacological differences and their clinical implications.Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Recent progress in natural products as DPP-4 inhibitors.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture.Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
P2860
Q30417363-AE650511-9B52-4816-AF73-7A7DD6406E60Q33706160-407C9460-51EA-45B5-9160-937BF3794773Q34198223-B18AB25D-F8AC-414A-AF14-5403E7BC3EBEQ34347884-5834C638-64BF-4A14-9F6D-630B1602880FQ35988135-8F0E72FD-353D-4048-8458-62F75018A43EQ37195882-F13D5346-72BA-428A-BD9D-C87F980D8EACQ37652091-4FD8A872-3D97-42BB-91F1-E1BA4B7F69AFQ38078436-A2EAC22D-5666-456D-BB23-831453B52B4CQ38082848-EE36BA7F-8BD8-4BE3-A377-24314F5247DCQ38101993-2F2AB20F-D9E2-47EC-875F-49B657DB5213Q38113093-DF066554-0E29-4057-8ECE-47A8FF1ED92DQ38113095-6D6B25DE-C16E-445A-B317-27E2DC715557Q38126945-AF1DAC61-167F-4B21-BBDF-2DD3F6C7F151Q38130192-0BDAB0E6-8529-4111-8F4C-FEA66F0F595AQ38192053-9899CDE9-7F5B-45D5-BA13-BCFD908E8338Q38211597-431E40CC-F9DC-49A6-A2A1-9B10BBFCDC4BQ38244576-0C9F5E07-8403-4678-8E63-CD1A646CDE78Q38258938-29A6AD2F-6BF8-47A9-A1BF-9D513A1128A1Q38335751-5A25FA49-456B-4F58-B2EC-A73D5A1AD6DFQ38412153-E8FBA761-F2BE-4CE0-91DF-9BBAFAA3C0B6Q38524167-EA15D8D9-8E61-4A81-BFCA-D76CC043FF97Q38647717-58257BE7-32BD-4CA5-BF67-3339F939CEE0Q38833312-F35D99B3-847C-41D6-AB02-F61F8CE32CD1Q43470326-14D89F76-161C-4FCE-A3B5-3261FAA17823Q46739133-793D0DB6-0F72-42F8-8153-8280FBD4ADFEQ47305063-B1CED7DE-F80A-4999-B5DF-5EEDF1B31D42
P2860
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@en
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@nl
type
label
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@en
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@nl
prefLabel
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@en
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@nl
P2093
P1476
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
@en
P2093
Jamie S Shelburne
Julienne K Kirk
Kathleen R Richard
P304
P356
10.1016/J.CLINTHERA.2011.09.028
P577
2011-11-08T00:00:00Z